Methazolamide (trade name Neptazane) is a potent carbonic anhydrase inhibitor. It is indicated in the treatment of increased intraocular pressure (IOP) in chronic open-angle glaucoma and secondary glaucoma. Also it is used preoperatively in acute angle-closure (narrow-angle) glaucoma where lowering the IOP is desired before surgery.
This drug has displayed teratogenic effects in rats. Compared to another drug in the same class, acetazolamide, methazolamide requires a lower dose when administered to patients.
Recently, research has also uncovered a potential new role for this drug, addressing tau toxicity, a theorized cause for diseases such as Alzheimer’s. [1]
References
- ^ Lopez A, Siddiqi FH, Villeneuve J, Ureshino RP, Jeon HY, Koulousakis P, et al. (October 2024). "Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion". Nature Chemical Biology: 1–11. doi:10.1038/s41589-024-01762-7. PMID 39482469.
Further reading
- Iyer GR, Bellantone RA, Taft DR (February 1999). "In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics". Journal of Pharmacokinetics and Biopharmaceutics. 27 (1): 45–66. doi:10.1023/A:1020630712388. PMID 10533697. S2CID 24294348.
- RxList. "Neptazane". Archived from the original on August 12, 2006. Retrieved August 20, 2006.
- Shirato S, Kagaya F, Suzuki Y, Joukou S (April 1997). "Stevens-Johnson syndrome induced by methazolamide treatment". Archives of Ophthalmology. 115 (4): 550–553. doi:10.1001/archopht.1997.01100150552021. PMID 9109770.
- Skorobohach BJ, Ward DA, Hendrix DV (February 2003). "Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs". American Journal of Veterinary Research. 64 (2): 183–187. doi:10.2460/ajvr.2003.64.183. PMID 12602587.